Alexza licenses Staccato nicotine delivery to Cypress Bioscience

With all the recent noise about whether so-called e-cigarettes should be regulated by the FDA as drug-delivery devices, it shouldn't be forgotten that there are companies that produce nicotine-delivery products aimed at smoking cessation. And these companies are willing to go through the required clinical trials. One of them is Mountain View, CA-based Alexza Pharmaceuticals, which recently announced that it is licensing its Staccato nicotine technology to Cypress Bioscience. 

"The Staccato system is a broad technology platform and Alexza has more Staccato-based product candidates than we can currently afford to develop on our own," says Alexza CEO Thomas King in a statement. "In early July, we outlined our strategy to advance Staccato-based product candidates into development through self-funding and through collaborations."

Cypress will pay Alexza $5 million upfront for the license. After the completion of certain preclinical and clinical milestones, Cypress will pay Alexza an additional $1 million. 

According to Alexza, Staccato nicotine is designed to help smokers quit by addressing both the chemical and behavioral components of nicotine addiction. It combines nicotine replacement through inhalation with a "user-friendly" drug delivery device, the company says. The company also claims that users could electronically reduce their overall daily dose of nicotine and ultimately quit smoking using the device. 

- read the Alexza release
- watch an animation of Staccato in action

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.